Sanofi granted Regeneron development and commercialization rights to antibodies targeting platelet derived growth factor (PDGF) and angiopoietin 2 (ANG2; ANGPT2)

Sanofi

France / Large-Cap Biopharma (>=$50 billion)

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Regeneron Pharmaceuticals Inc.

U.S. / Mid-Cap Biopharma ($1-$50 billion)

$25,785.0m on 05/03/2013 [market cap]

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced